Could This Game-Changing FDA Approval Mean Profit for Johnson & Johnson Shareholders?
Earlier this month, the U.S. Food and Drug Administration approved Johnson & Johnson’s (NYSE:JNJ) Invega Hafyera, the first and only twice-yearly injectable drug to treat schizophrenia.
This FDA approval builds on Johnson & Johnson’s injectable schizophrenia…
